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The lack of a large animal transplantable tumor model has limited the study of
novel therapeutic strategies for the treatment of liquid cancers. Swine as a species
provide a natural option based on their similarities with humans and their already
extensive use in biomedical research. Specifically, the Massachusetts General Hospital
miniature swine herd retains unique genetic characteristics that facilitate the study of
hematopoietic cell and solid organ transplantation. Spontaneously arising liquid cancers
in these swine, specifically myeloid leukemias and B cell lymphomas, closely resemble
human malignancies. The ability to establish aggressive tumor cell lines in vitro from
these naturally occurring malignancies makes a transplantable tumor model a close
reality. Here, we discuss our experience with myeloid and lymphoid tumors in major
histocompatibility characterized miniature swine and future approaches regarding the
development of a large animal transplantable tumor model.
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INTRODUCTION
Malignancies of the hemolymphatic system in swine were ﬁrst reported as early as 1865(Bostock
and Owen, 1973) but generally, there are limited reports describing neoplasias in swine. This is
partly due to the fact that most swine die at a relatively young age, either slaughtered for food or
used in biomedical research. As of yet, there is no large animal tumor model available that can be
reliably induced and consistently reproduced. The vast majority of documented cases of leukemias
and lymphomas in veterinary oncology are in the domestic population (Schiﬀman and Breen,
2015). Liquid neoplasias have been reported in farm animals; however, these are uncommon due to
the lack of desire for a clinical workup and preference for euthanasia to minimize animal suﬀering.
Here, we will discuss how swine provide an attractive large animal model for the study of cancer
biology and its treatment. Speciﬁcally, theMassachusetts General Hospital (MGH)miniature swine
herd retains unique genetic characteristics that facilitate the study of hematopoietic cell (HCT) and
solid organ transplantation (SOT; Hanekamp et al., 2011). A signiﬁcant incidence of spontaneous
chronic myeloid leukemias and herpesvirus associated B cell lymphomas have been reported in the
MGHminiature swine herd, making it a viable option for the development of a large animal tumor
model (Hanekamp et al., 2011).
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SWINE AS A LARGE AMINAL RESEARCH
MODEL
The use of large animal models in biomedical research remains
controversial. Ethical justiﬁcations and selection of a less
expensive model must continuously be addressed to private,
government, and academic reviewers. However, the use of large
animal models is important as murine studies often fail to
translate clinically (Hunter and Williams, 2002; Adelman et al.,
2006). Among the available large animals in biomedical research,
primate models have the obvious advantage of physical and
physiological similarity to humans, but there are several barriers
to their use including strict regulation standards, expense,
negative societal impression, diﬃculty in breeding and handling,
prolonged time to sexual maturity and potential for infectious
disease. Canine models are a more practical option and have
been widely used (Cain and Champlin, 1989; Ladiges et al., 1990;
Storb et al., 2001; Zaucha et al., 2001). However, no canine
tumor model exists yet, and compared to swine, their use is
less favored because of their status as a common companion
animal. Alternatively, swine are an ideal experimental model for
several reasons including ease of breeding and handling, short
gestation periods, large litters, short time to sexual maturity,
and an anatomy and physiology that closely resembles that of
humans (Laber et al., 2002; Swindle et al., 2012). However, as
with any animal model, there are limitations to the swine model.
The ability to consistently reproduce ﬁndings in outbred species,
though clinically relevant, remains the biggest challenge in terms
of developing a tumor model.
Although murine studies have historically been critical in the
study of cancer biology and immunological diseases, attempts at
extrapolation to large animals or clinical studies have often been
unsuccessful, especially with respect to studies of transplantation
(Bortin, 1970; van Bekkum, 1984; Storb, 2003). This can be
appreciated in studies of immunological tolerance, in which
numerous approaches to allograft tolerance have been developed
in mice, but very few have proven successful in clinical studies
(Storb, 2003). Over 30 years ago, NIH researcher Dr. David
Sachs initiated a selective breeding program of miniature swine
to develop and maintain a large animal model for studies of
transplantation biology (Sachs et al., 1976). Through years of
selective breeding, Sachs et al. (1976) were able to “ﬁx” the major
histocompatibility (MHC) genes of the miniature swine herd,
while retaining variability tominor antigens (miHAs; Pennington
et al., 1981a,b; Mezrich et al., 2003). The homozygosity of MHC
genes has made the MGH miniature swine a valuable model
in that diﬀerent clinical transplant scenarios can be mimicked
(full MHC match, complete MHC mismatch, haploidentical
match, etc). One line of swine was selectively inbred, which
will refer to as the “SLAdd” line (swine leukocyte antigen -
dd), aiming to achieve complete syngeneity (Hanekamp et al.,
2011), as has been done in mice. Currently, the SLAdd line
has reached a coeﬃcient of inbreeding of >94%. Despite not
yet being 100% genetically identical, skin and organ allografts
transplanted between animals within this line are consistently
accepted without any immunosuppression (Mezrich et al., 2003).
Extrapolating from these data, spontaneous tumors arising in
this line can be harvested expanded in vitro and cryopreserved
for in vivo transfer studies, providing the foundation for
a transplantable swine tumor model. Here, we discuss our
experience with myeloid and lymphoid tumors within the MGH
miniature swine and future goals of a large animal tumor model.
CHRONIC MYELOGENOUS LEUKEMIA
IN SWINE
Recently, we reported a signiﬁcant incidence of spontaneous
myeloid leukemias in the inbred SLAdd line of the MGH
miniature swine herd and demonstrated that swine chronic
myelogenous leukemias (CML) closely resembled human CML
(Duran-Struuck et al., 2010). In our study, two swine CML
cell lines were karyotyped to assess the presence of a speciﬁc
translocation or mutation, similarly to the t(9;22) translocation,
or philadelphia chromosome (Ph+), which is well documented
in the majority of human CMLs (Oettel et al., 1994; Marks
et al., 2010; Chereda and Melo, 2015). In both cases, a
shortened chromosome armwas identiﬁed (Duran-Struuck et al.,
2010), reminiscent of the classical Ph+ in humans. PCR was
performed using BCR–ABL gene-speciﬁc primers to determine
whether the genetic change was identical (or similar) to the
Ph+ chromosome in human CML (Chereda and Melo, 2015).
Sequences surrounding the known chromosomal breakpoint of
the BCR and ABL genes in the human K562 CML cell line were
compared to the available porcine or bovine sequences to identify
conserved regions for primer design. Two bands of 300 and
500 nucleotides were detected in the pig while a single distinct
band of 450 nucleotides was present in the K562 sample. Due
to diﬀerences in chromosome numbers between humans and
swine (23 pairs for humans and 19 for swine), we could not
directly translate the t(9;22) translocation observed in humans
CMLs. Future genetic studies of these swine tumors may provide
a platform for novel therapeutic approaches for human tumors
sharing similar genetic defects.
AN INDUCIBLE SWINE CML MODEL
Central to the development of many murine tumor models
has been the establishment of in vitro oncologic cell lines.
Similarly, characterization of tumor cell lines derived from inbred
miniature swine and adaptation for in vivo growth is a possibility.
Several CML cell lines from the SLAdd inbred line were previously
isolated from aﬀected animals (Cho et al., 2007; Duran-Struuck
et al., 2010), and aggressive subclones were selected out by serial
passages in vitro. In vivo growth of a CML cell line originating
in animal 14736 was assessed after direct inoculation into naïve
swine conditioned with gamma irradiation (ranging from 100
to 500 cGy). Subcutaneous (SQ) injection of the 14736 CML
cell line into an animal conditioned with 300 cGy total body
irradiation (TBI) resulted in SQ tumor growth, but not systemic
growth (Cho et al., 2007). Systemic tumorigenesis (with mostly
lung involvement) required at least 500 cGy of TBI. Though
non-myeloablative, 500 cGy of TBI proved to be signiﬁcantly
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immunosuppressive and animals often died of infections and not
due to the induced neoplasm. If animals received less irradiation
(<500 cGy), tumor cells did not grow in vivo (Duran-Struuck,
unpublished data). Injection of CML cell lines directly into the
bone marrow (intra-BM) of SLAdd swine conditioned with low
levels of TBI (100–200 cGy) also did not lead to systemic leukemic
growth. BM biopsies from one animal that had been infused with
intra-BM CML were cultured in vitro. The resulting cell line
was phenotypically and morphologically similar to the injected
CML but could not be diﬀerentiated from a potential de novo
CML. Diﬃculties in achieving CML disease in this model may
be explained by the presence of minor antigen incompatibilities
(miHAs), which may exist between host and tumor despite being
MHC matched. Inbreeding can induce the loss (or gain) of
expression of an immunogenic protein (secondary to a mutation)
to which the animal may have not been made tolerant during
thymic T cell education. Thus, host “rejection” of infused tumor
cells can occur despite being MHC matched in the context
of insuﬃcient immunosuppression. This is supported by SQ
tumor growth in the animal conditioned with high amounts of
irradiation (500 cGy) while animals that received lower amounts
of irradiation (100–300 cGy) did not exhibit any tumor growth.
Two other explanations for failed tumor growth can be attributed
to the loss of growth characteristics (growth factors, adhesion
molecules, etc.) of the in vitro passaged CML tumor cells and the
requirement of a longer time to develop in vivo than what was
designed in the IACUC protocol.
To assess whether the in vitro culture process aﬀected tumor
cell growth capacity in vivo, cell lines were passaged in vivo in
mice. Tumors have historically been expanded across xenogeneic
barriers in immunodeﬁcient mice (NOD/SCID) and have been
successful in selecting for aggressive tumor subclones (Waller
et al., 1993; Adam et al., 2007; Schook et al., 2015). Though
not ideal to expand tumor cell lines in animals diﬀerent from
the original host species, this approach ensures that tumor cells
retain their in vivo growth capacity. 14736 CML tumor cells
did not grow in NOD/SCID mice (Cho et al., 2007), but did
lead to CML disease in NSG (NOD/SCID gamma −/−) mice
(Schenk et al., manuscript in preparation), albeit requiring over
4 months. These results suggest that the innate immune system
of NOD/SCID mice may have been suﬃcient to “reject” the
tumor cells, as NSG mice lack macrophages and NK cells. Thus,
spontaneous swine CML lines can be successfully expanded
in vivo, and transfer studies into swine are forthcoming.
PORCINE LYMPHOTROPIC
HERPESVIRUS (PLHV) INDUCED B CELL
LYMPHOMAS
A major area of study in MGH miniature swine for the
past 30 years has been the use of HCT to induce mixed
hematopoietic chimerism without GVHD, both for solid organ
tolerance and treatment strategies of hemolymphatic neoplasias.
Currently, a major complication of both HCT and SOT is
the development of post-transplant lymphoproliferative disease
(PTLD). PTLD is observed in immunosuppressed transplant
patients, but similar lymphoproliferative processes can present
in those naturally immunosuppressed, such as AIDS patients
(Bollard et al., 2004; Abu-Elmagd et al., 2009). Under the cover
of immunosuppression and depressed CD8+ T cell immunity,
the B cell population aggressively expands as a result of primary
infection or reactivation of a herpes virus, most commonly
Epstein Barr virus (EBV; Heslop et al., 1996; Lucas et al., 1996).
Unfortunately, the variability of the human patient population,
both clinically and pathologically, complicates the ability to
study this disease (DiNardo and Tsai, 2010). Murine models
of PTLD involving immunodeﬁcient mice injected with human
PTLD lines and mice infected with murine gamma herpesvirus
are unreliable and do not accurately model human disease
(Schiﬀman and Breen, 2015).
In contrast, swine have been shown to be an excellent
model for the study of PTLD. Immunosuppressed swine
undergoing HCT or SOT develop B-cell expansions with a
clinical presentation that closely resembles human PTLD (Huang
et al., 2001; Matar et al., 2015). Similarly to human PTLD’s
association with EBV, swine PTLD is associated with primary
infection or reactivation of a gamma herpesvirus, porcine
lymphotropic herpesvirus-1 (PLHV-1; Doucette et al., 2007). In
a model of haploidentical HCT, immunosuppressive regimens
consisting of T-cell depletion using CD3-immunotoxin, 1000 cGy
of thymic irradiation, and a 30–60 days course of cyclosporine
A consistently (40–50%) resulted in the development of B cell
lymphomas post-transplant (Cho et al., 2004; Cina et al., 2006;
Matar et al., 2015). When thymic irradiation was eliminated as
part of the conditioning regimen, only 1/23 animals developed
PTLD. However, in the absence of thymic irradiation, T
cell depletion was poor, resulting in inconsistent stem cell
engraftment. 100 cGy of TBI was added to the conditioning
regimen in an attempt to decrease the incidence of PTLD
while allowing for stem cell engraftment. Subsequently, only
15% developed PTLD, while the majority of animals successfully
engrafted (Matar et al., 2015). Matar et al. (2015) recently
explored the eﬀect of thymic and TBI on the incidence of PTLD
in this model and concluded that thymic irradiation was a risk
factor for PTLD development via its depleting eﬀect on the
absolute number of T cells. Further, the use of LDH as a serum
marker for swine PTLD was validated (Figure 1). As in humans,
B cell expansion in the context of swine PTLD is mirrored by
increases in LDH (Boothpur and Brennan, 2008), even before
clinical signs of PTLD such as lymphadenopathy (Figure 2). This
was also shown to be diagnostically valuable in swine CMLs
(Duran-Struuck et al., 2010) which mirrored the LDH increases
observed in human CMLs and reinforcing the swine tumor
model.
In clinical practice, the standard treatment approach for PTLD
is the reduction of immunosuppression and sometimes followed
by a second treatment modality if necessary, such as rituximab
(anti-CD20 mAb) or chemotherapy (DiNardo and Tsai, 2010).
Removing immunosuppression in the transplant setting is often
complicated by organ rejection or graft-versus-host disease in
the setting of allogeneic bone marrow transplantation (BMT).
Chemotherapy remains an eﬀective, yet toxic treatment option,
and rituximab though eﬀective, does not control PTLD in all
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FIGURE 1 | LDH, BUN and Creatinine in a pig developing
post-transplant lymphoproliferative disease (PTLD). Kidney values
remained relatively constant while LDH levels rose acutely.
FIGURE 2 | Post-transplant lymphoproliferative disease in miniature
swine. (A) Total B cell burden in an animal developing PTLD. B cells tripled in
number within 24 h. (B) Lymphadenopathy (inguinal area). (C) Perihilar
lymphadenopathy (arrow shows trachea). Cranial aspect of the animal is to
the left of the image. (D) H & E section demonstrating cellular infiltrate in a
lymph node (20×).
cases. In the context of swine PTLD following BMT, reduction
or discontinuation of immunosuppression only sometimes leads
to PTLD resolution, but GVHD is a common consequence
(Duran-Struuck et al., manuscript in preparation). In the study
cited above, of 11 animals that developed PTLD, only two cases
resolved after discontinuation of cyclosporine, and those two
animals subsequently developed GVHD. This naturally induced
model of PTLD following BMT can be used to study novel
treatment approaches such as new antivirals or the use of in vitro
primed host CD8+ T cells as a cellular therapy for primary or
refractory PTLD.
SWINE PTLD TUMOR LINES
Although this naturally induced model oﬀers a clinically
relevant opportunity which to study PTLD, it is limited by the
inconsistency in PTLD incidence (40–50%) and the logistics and
cost involved in a BMT or SOT. Alternatively, swine PTLD
tumors have been successfully harvested from various involved
organs, including lymph nodes and spleen, and expanded in vitro
with the intention of establishing an immortal cell line that
can reliably induce PTLD when introduced into a naïve animal
from the same inbred line. To test the ability of these cell
lines to grow in vivo, as a preliminary experiment, a PTLD
B cell lymphoma line was established from animal 13271 and
infused intravenously into unconditioned NSG (NOD/SCID IL-
2r gamma−/−) mice (Schenk et al., manuscript in preparation).
In general, an average of 10 × 106 PTLD cells was infused per
mouse. At this dose, we observed successful “engraftment” of
tumor cells with 100% lethality within 57–70 days. Subsequently,
the same PTLD cell line was tested in two MHC matched
swine. Animals were preconditioned with a non-myeloablative
protocol that has previously been permissive for the induction
of PTLD. Animals received 100 cGy of TBI on day −2, T cell
depletion with a recombinant CD3-immunotoxin twice daily
from day−4 to day−1, and were maintained under cyclosporine
coverage for 60 days. In total, each animal received three doses
of approximately 300 × 106 tumor cells/kg over a period of
1 week, totaling 900 × 106 tumor cells/animal. Tumor cells
were infused intravenously (IV) and/or intraosseously (IO),
with the intention of overwhelming the animals’ tumor clearing
capacity and allowing for successful “engraftment” of tumor
cells. Unfortunately, none of the animals developed PTLD. B
cell counts normalized soon after infusion and an increase
in B cells was only observed during the peri-infusion period
as determined by ﬂow cytometry analysis. Thus, PTLD tumor
cells selected in vitro for their growth ability and which had
successfully engrafted in NSG mice did not cause overt PTLD in
immunocompromised miniature swine. A limitation of this non-
myeloablative approach is the potential for radiation resistant
T cells to “reject” the tumors via minor antigen incompatibility
(Nadazdin et al., 2011; Zhang et al., 2012) or TLR ligation (Yu
et al., 2012). Thus, conditioning regimens that have a stronger
depleting eﬀect on T cells, such as the use of thymic irradiation
which has been shown to be very conducive to the development
of PTLD, may be required to better induce tumor growth.
From an immunologic standpoint, it is crucial to understand
themethod of “graft” (tumor) loss in this model. There are several
possibilities for the lack of tumor cell engraftment including an
active rejection of tumor cells by residual host defenses, evasion of
host immune responses by “hiding” in an immune privileged site
(such as the bone marrow), simply being ignored by host defenses
in the circulation, or alternatively, tumor cells may have died
due to lack of ﬁtness, without an immunological attack. In our
studies, mixed lymphocyte reactions (MLR) and cell mediated
cytolysis (CML) assays did not suggest a cellular sensitization
against tumor antigen(s). This implies the mechanism of graft
loss was possibly non-immunologic, either via clearance from the
circulation or lack of ﬁtness in the swine environment.
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Due to the fact that host and tumor cells are fully MHC
matched, it is diﬃcult to distinguish tumor cells after infusion,
as they could be residing in the marrow or lymph nodes without
surviving in the peripheral blood. As a method to distinguish
and monitor tumor cells in vivo, a green ﬂuorescent protein
(GFP) gene was transduced into the PTLD tumor cell line
using a lentivirus vector. GFP(+) tumor cells were then sorted
and expanded. Interestingly, GFP+ tumor cells grew faster
in vitro compared to GFP(−) tumor cells. When NSG mice
were challenged with GFP(+) tumor cells, we observed a faster
onset of disease as well as more extensive organ involvement,
suggesting a more aggressive tumor. One MHC matched swine
was infused with GFP(+) PTLD under the same conditioning
regimen as used previously. The cells were monitored via ﬂow
cytometry and were undetectable after 48 h, suggesting they were
either cleared from the circulation or sequestered. Again, no
sensitization was observed by MLR or CML assays indicating
a non-immunologic mechanism of graft loss (Schenk et al.,
manuscript in preparation).
CONCLUSION AND FUTURE
DIRECTIONS
Spontaneously arising hemolymphatic tumors in the MGH
miniature swine herd, speciﬁcally myeloid leukemias and B
cell lymphomas, closely resemble human malignancies, making
the MGH swine an valuable model for the development
of a clinically applicable large animal tumor model based
on their unique genetic characteristics. Future approaches
focusing on reproducibility will include several strategies,
including; (i) optimizing transplant protocols to induce
tumor cell engraftment, (ii) ex-vivo transduction of porcine
hematopoietic stem cells with known oncogenes (Adam
et al., 2007), and (iii) the introduction of oncogenes
via retroviral vectors (Adam et al., 2007). Alternatively,
backcrossing the MHC characterized mini-swine with the
ﬁrst naturally occurring severe combined immunodeﬁcient
(SCID) pig line. This SCID pig has already been shown
to accept human tumor xenografts, and thus can enhance
the engraftment of allogeneic tumor transfer studies (Waide
et al., 2015). In summary, the importance of a consistently
reproducible large animal tumor model cannot be understated,
as it will facilitate the study of these lethal malignancies
and test reliably novel therapeutic strategies for clinical
applications.
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